What are the current recommended antiretroviral therapy regimens for HIV infection and is there a cure?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

HIV Treatment and Cure

All individuals with HIV should be started on antiretroviral therapy (ART) immediately upon diagnosis, and there is currently no cure for HIV—treatment is lifelong. 1

Current Recommended Initial ART Regimens

The most recent 2024 International Antiviral Society-USA guidelines establish clear first-line therapy options 1:

Preferred Initial Regimens

For most people with HIV, initial therapy should consist of an integrase strand transfer inhibitor (InSTI)—specifically bictegravir or dolutegravir—combined with 2 nucleoside reverse transcriptase inhibitors (NRTIs). 1 These regimens are prioritized because they are:

  • Highly potent with durable viral suppression
  • Convenient (often single-tablet once-daily dosing)
  • Well-tolerated with minimal side effects
  • High genetic barrier to resistance

The specific combinations include:

  • Bictegravir/tenofovir alafenamide/emtricitabine (single tablet, once daily)
  • Dolutegravir plus tenofovir alafenamide/emtricitabine or tenofovir disoproxil fumarate/emtricitabine
  • In some cases, dolutegravir/lamivudine (2-drug regimen) 1

Alternative Options

Long-acting injectable therapy with cabotegravir plus rilpivirine administered every 4-8 weeks is now available for patients who prefer not to take daily oral medications or struggle with adherence to daily therapy 1, 2. This represents a major advance, allowing treatment as infrequently as every 2 months.

Special Populations

During pregnancy: Dolutegravir-based regimens are recommended, combined with tenofovir disoproxil fumarate/emtricitabine or tenofovir alafenamide/emtricitabine 3. Women already on effective ART when becoming pregnant do not need to switch 3.

With active tuberculosis: Use dolutegravir (50 mg twice daily), efavirenz, or raltegravir (800 mg twice daily) plus 2 NRTIs when receiving rifamycin-based TB treatment. Bictegravir is contraindicated with rifampin due to drug interactions 3.

With cryptococcal meningitis: Delay ART initiation for 4-6 weeks after starting antifungal therapy to reduce mortality risk 3.

Timing of ART Initiation

Start ART as soon as possible after HIV diagnosis—including immediately at the first clinic visit if the patient is ready 3. This "rapid start" approach improves outcomes and reduces transmission risk. The evidence strongly supports removing structural barriers that delay ART receipt 3.

For most opportunistic infections, initiate ART within 2 weeks of starting treatment for the infection 3. The exceptions noted above (TB with low CD4 counts and cryptococcal meningitis) require delayed initiation to prevent immune reconstitution inflammatory syndrome complications.

Monitoring and Switching Therapy

Check HIV viral load 1 month after starting or switching ART 3. The goal is viral suppression to undetectable levels (<200 copies/mL, though many assays detect <20-50 copies/mL).

When to Switch Regimens

Switch therapy for:

  • Virologic failure (confirmed HIV RNA >200 copies/mL): Obtain resistance testing while on the failing regimen, then switch promptly to a new active regimen based on current and past resistance results 3
  • Adverse effects or intolerance
  • Convenience or adherence issues
  • Drug interactions
  • Patient preference

In virologically suppressed patients, switching from 3-drug to 2-drug regimens is appropriate when both agents remain fully active. Options include dolutegravir/rilpivirine, dolutegravir/lamivudine, or boosted protease inhibitor with lamivudine 3.

Critical Pitfall: HBV Co-infection

Patients with HIV/HBV co-infection must continue tenofovir alafenamide or tenofovir disoproxil fumarate when switching regimens 3. Switching to lamivudine or emtricitabine alone without tenofovir will not maintain HBV suppression and risks hepatitis flare—this is contraindicated 3.

Is There a Cure?

No, there is currently no cure for HIV. 4, 5 Despite decades of research, HIV persists in latent viral reservoirs within cells that ART cannot eliminate 4. Treatment remains lifelong and indefinite 5.

Emerging Curative Strategies (Investigational)

Research is exploring several approaches, but none are clinically available 4:

  • Gene editing (CRISPR/Cas9) to directly eliminate viral DNA
  • Stem cell transplantation (only 2-3 documented cases of apparent cure worldwide, not scalable)
  • Latency-reversing agents ("shock and kill" strategies)
  • Latency-silencing approaches (permanent viral suppression)
  • Therapeutic vaccines and immunotherapy

These remain experimental and face significant challenges regarding safety, scalability, and accessibility 4.

Expected Outcomes with Current Treatment

With consistent ART adherence, people with HIV now have a life expectancy approaching that of the general population 6. Modern regimens achieve durable viral suppression in the majority of patients, restore immune function, prevent AIDS-related complications, and eliminate sexual transmission risk (U=U: undetectable equals untransmittable) 6, 1.

Important Caveats

  • Weight gain and metabolic complications have been linked to certain antiretrovirals, particularly integrase inhibitors and tenofovir alafenamide 1, 2. Monitor weight, lipids, and glucose; novel strategies to manage these complications are needed.
  • Non-AIDS comorbidities (cardiovascular disease, cancer, cognitive impairment) require ongoing management as patients age 1, 2
  • Adherence support is critical—even brief treatment interruptions risk viral rebound and resistance development
  • Drug interactions must be reviewed before any medication changes, particularly with tuberculosis drugs, hormonal contraceptives, and acid-reducing agents 3

The 2024 IAS-USA guidelines represent the most current, evidence-based approach to HIV management, emphasizing immediate treatment initiation, integrase inhibitor-based regimens, and addressing health equity to end the HIV epidemic 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.